Hybrozyme technology utilizes domain swapping of two structurally similar enzymes based on protein engineering while keeping the inherent catalytic mechanism but improving the conformational flexibility and thermal stability of the target enzyme. Alteogen, Inc. has applied its Hybrozyme technology to a human hyaluronidase, PH20, which has been widely used to improve the absorption of drug biologics delivered via subcutaneous injection. The PH20 variants based on Hybrozyme technology showed improved enzymatic activity and thermal stability compared with wild-type PH20. The expression of PH20 variants in CHO cells was also higher than that of wild-type PH20.
* Improved enzymatic activity and thermal stability
* Enhanced protein expression in CHO cells and higher productivity
Alteogen’s human PH20 proteins not only have economic value because of higher productivity in CHO cells but also demonstrate enhanced protein function resulting from better physico-chemical properties compared with wild-type PH20. As a result, Alteogen’s PH20 products use less amount of protein for clinical applications and have a longer shelf-life. Alteogen, Inc. has a line-up of PH20 variants appropriate for the development of both biosimilars and new drug biologics for human injection.